| 孙孟华,侯永茂,刘军利,等.血清沉默信息调节因子 6、人激肽释放酶抑制剂对急性心肌梗死伴心力衰竭预后的预测价值[J].安徽医药,2024,28(11):2222-2226. |
| 血清沉默信息调节因子 6、人激肽释放酶抑制剂对急性心肌梗死伴心力衰竭预后的预测价值 |
| The predictive value of serum SIRT6 and Kallistatin expression in patients with acute mycardial infarction and heart failure for prognosis |
| |
| DOI：10.3969/j.issn.1009-6469.2024.11.022 |
| 中文关键词: 心肌梗死 心力衰竭 沉默信息调节因子 6 人激肽释放酶抑制剂 预测价值 |
| 英文关键词: Myocardial infarction Heart failure Silent information regulator 6 Kallistatin Predictive value |
| 基金项目:河南省医学科技攻关计划项目( LHGJ20190809) |
|
| 摘要点击次数: 403 |
| 全文下载次数: 1 |
| 中文摘要: |
| 目的探讨急性心肌梗死伴心力衰竭病人血清沉默信息调节因子 6(SIRT6)、人激肽释放酶抑制剂( Kallistatin)的表达水平对预后的预测价值。方法选择 2021年 1月至 2023年 1月安阳市人民医院收治的急性心肌梗死伴心力衰竭病人 123例作为疾病组，治疗 90 d后将其分为预后不佳组( n=77)和预后良好组( n=46)选取同一时期进行健康体检的 123例志愿者作为对照组。采用酶联免疫吸附法( ELISE)检测血清 SIRT6、Kallistatin表达水平，，收集入选者心功能指标［左室收缩末期容积指数(LVESVI)、左室射血分数( LVEF)、左室舒张末期容积指数( LVEDVI)］；采用 Pearson法分析急性心肌梗死伴心力衰竭病人血清 SIRT6、Kallistatin与 LVESVI、LVEF、LVEDVI的相关性；运用 ROC曲线评估血清 SIRT6、Kallistatin水平对急性心肌梗死伴心力衰竭病人预后不佳的预测价值。结果与对照组相比，急性心肌梗死伴心力衰竭病人 LVEF［( 56.98±8.29)%比( 68.21± 10.12)%］、血清 SIRT6［( 5.08±0.87)μg/L比( 7.12±1.26)μg/L］、 Kallistatin［( 6.51±1.01)mg/L比( 8.24±1.38)mg/L］水平较低( P< 0.05)LVEDVI、LVESVI较高(均 P<0.05)且病人血清 SIRT6、Kallistatin与 LVEF呈正相关，与 LVEDVI、LVESVI呈负相关性(均 P<0.01)，。与预后良好组相比，预后不佳组血，清 SIRT6、Kallistatin水平均明显较低( P<0.05)；血清 SIRT6、Kallistatin预测急性心肌梗死伴心力衰竭病人预后不佳的 AUC分别为 0.860、0.884，血清 SIRT6、Kallistatin联合检测预测预后不佳的 AUC(0.945)高于单独检测(Z二者联合 -SIRT6=2.72、Z二者联合 -Kallistatin=2.18，P=0.007、0.029)。结论急性心肌梗死伴心力衰竭病人血清 SIRT6、Kallistatin水平明显降低，二者联合对急性心肌梗死伴心力衰竭病人预后具有较好的预测价值。 |
| 英文摘要: |
| Objective To explore the predictive value of serum silent information regulator 6 (SIRT6) and Kallistatin expression inpatients with acute myocardial infarction and heart failure for prognosis.Methods A total of 123 patients with acute myocardial infarction with heart failure admitted to Anyang People's Hospital from January 2021 to January 2023 were selected as the disease group, After 90 days of treatment, they were divided into poor prognosis group (n=77) and good prognosis group (n=46), and 123 volunteers whounderwent physical examination during the same period were selected as the control group. Enzyme linked immunosorbent assay(ELISE) was applied to detect the expression levels of serum SIRT6 and Kallistatin, the left ventricular end-systolic volume index (LVESVI), left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume index (LVEDVI) were collected; Pearson method was applied to analyze the correlation between serum SIRT6, Kallistatin, LVESVI, LVEF, and LVEDVI, in patients with acute myocardial infarction and heart failure; and ROC curve was applied to evaluate the predictive value of serum SIRT6 and Kallistatin levelsfor poor prognosis in patients with acute myocardial infarction and heart failure.Results The serum levels of SIRT6[(5.08±0.87)μg/L vs. (7.12±1.26)μg/L], Kallistatin[(6.51±1.01)mg/L vs. (8.24±1.38)mg/L],and LVEF[(56.98±8.29)% vs. (68.21±10.12)%] in patients withacute myocardial infarction and heart failure were lower than those in the control group (P<0.05), LVEDVI and LVESVI were obviouslyhigher than the control group (both P<0.05). The serum levels of SIRT6 and Kalistatin in patients with acute myocardial infarction andheart failure were positively correlated with LVEF, but negatively correlated with LVEDVI and LVESVI (all P<0.01). Serum levels of SIRT6 and Kallistatin in poor prognosis group were significantly lower than those in good prognosis group (P<0.05); the AUC predictedby serum SIRT6 and Kalistatin for poor prognosis in patients with acute myocardial infarction and heart failure was 0.860 and 0.884, respectively, the AUC predicted by the combination of serum SIRT6 and Kalistatin (0.945) was higher than that by individual testing (Zcombination-SIRT6=2.72,Zcombination-Kalistatin=2.18,P=0.007,0.029).Conclusion The serum levels of SIRT6 and Kallistatin in patients with acute myo cardial infarction and heart failure are obviously reduced, and the combination of the two has good predictive value for the prognosis ofpatients with acute myocardial infarction and heart failure. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
